This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sears, S D Articles by Clements, M L Search for Related Content PubMed PubMed Citation Articles by Sears, S D Articles by Clements, M L

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1987 October; 31(10): 1470-1473

Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus.

S D Sears and M L Clements

Johns Hopkins University Center for Immunization Research, Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205.

ABSTRACT

The prophylactic efficacy of a low dose (100 mg) of amantadine hydrochloride against experimental challenge with influenza A/Texas/1/85 (H1N1) wild-type virus was determined in healthy adult volunteers in a placebo-controlled, double-blind, randomized trial. No side effects of the 100-mg dose were observed in the amantadine-treated volunteers. Compared with placebo, 100 mg of amantadine significantly reduced the frequency of illness (9 of 22 versus 2 of 22 volunteers, P less than 0.04) and provided 78% protection against influenza illness. The two ill volunteers in the amantadine group had rhinitis only, whereas most of the ill placebo controls developed both systemic and upper-respiratory-tract illness. Wild-type virus was recovered from 50% of the amantadine-treated volunteers, compared with 82% of the placebo controls. Of note, the infected amantadine recipients shed 100 times less virus and shed virus for half as many days as did the infected placebo recipients. Although amantadine restricted viral replication, it did not interfere with the development of an antibody response to influenza virus. These results indicate that in adults experimentally challenged with influenza wild-type virus, 100 mg of amantadine is effective both in the prevention of influenza illness and in the restriction of virus replication.

---

Antimicrob Agents Chemother. 1987 October; 31(10): 1470-1473

This article has been cited by other articles:

• Carrat, F., Vergu, E., Ferguson, N. M., Lemaitre, M., Cauchemez, S., Leach, S., Valleron, A.-J. (2008). Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. Am J Epidemiol 167: 775-785 [Abstract] [Full Text]  
• Fenton, R. J., Morley, P. J., Owens, I. J., Gower, D., Parry, S., Crossman, L., Wong, T. (1999). Chemoprophylaxis of Influenza A Virus Infections, with Single Doses of Zanamivir, Demonstrates that Zanamivir Is Cleared Slowly from the Respiratory Tract. Antimicrob. Agents Chemother. 43: 2642-2647 [Abstract] [Full Text]  
• Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., Straus, S. E. (1999). Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza: Randomized Controlled Trials for Prevention and Treatment. JAMA 282: 1240-1246 [Abstract] [Full Text]  
• Hayden, F. G., Treanor, J. J., Betts, R. F., Lobo, M., Esinhart, J. D., Hussey, E. K. (1996). Safety and Efficacy of the Neuraminidase Inhibitor GG167 in Experimental Human Influenza. JAMA 275: 295-299 [Abstract]  
• Degelau, J., Somani, S. K., Cooper, S. L., Guay, D. R. P., Crossley, K. B. (1992). Amantadine-Resistant Influenza A in a Nursing Facility. Arch Intern Med 152: 390-392 [Abstract]